Structure-based discovery of dengue virus protease inhibitors

Suzanne M. Tomlinson, Robert D. Malmstrom, Andrew Russo, Niklaus Mueller, Yuan Ping Pang, Stanley Watowich

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Dengue virus belongs to the family Flaviviridae and is a major emerging pathogen for which the development of vaccines and antiviral therapy has seen little success. The NS3 viral protease is a potential target for antiviral drugs since it is required for virus replication. The goal of this study was to identify novel dengue virus (type 2; DEN2V) protease inhibitors for eventual development as effective anti-flaviviral drugs. The EUDOC docking program was used to computationally screen a small-molecule library for compounds that dock into the P1 pocket and the catalytic site of the DEN2V NS3 protease domain apo-structure [Murthy, K., Clum, S., Padmanabhan, R., 1999. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J. Biol. Chem. 274, 5573-5580] and the Bowman-Birk inhibitor-bound structure [Murthy, K., Judge, K., DeLucas, L., Padmanabhan, R., 2000. Crystal structure of dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. J. Mol. Biol. 301, 759-767]. The top 20 computer-identified hits that demonstrated the most favorable scoring "energies" were selected for in vitro assessment of protease inhibition. Preliminary protease activity assays demonstrated that more than half of the tested compounds were soluble and exhibited in vitro inhibition of the DEN2V protease. Two of these compounds also inhibited viral replication in cell culture experiments, and thus are promising compounds for further development.

Original languageEnglish (US)
Pages (from-to)110-114
Number of pages5
JournalAntiviral Research
Volume82
Issue number3
DOIs
StatePublished - Jun 2009

Fingerprint

Dengue Virus
Protease Inhibitors
Peptide Hydrolases
Antiviral Agents
Catalytic Domain
Flaviviridae
Small Molecule Libraries
Polyproteins
Active Immunotherapy
Drug Design
Virus Replication
Cell Culture Techniques
Pharmaceutical Preparations

Keywords

  • Dengue virus
  • Flavivirus
  • NS2B-NS3
  • Protease
  • Small-molecule inhibitor

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Tomlinson, S. M., Malmstrom, R. D., Russo, A., Mueller, N., Pang, Y. P., & Watowich, S. (2009). Structure-based discovery of dengue virus protease inhibitors. Antiviral Research, 82(3), 110-114. https://doi.org/10.1016/j.antiviral.2009.02.190

Structure-based discovery of dengue virus protease inhibitors. / Tomlinson, Suzanne M.; Malmstrom, Robert D.; Russo, Andrew; Mueller, Niklaus; Pang, Yuan Ping; Watowich, Stanley.

In: Antiviral Research, Vol. 82, No. 3, 06.2009, p. 110-114.

Research output: Contribution to journalArticle

Tomlinson, SM, Malmstrom, RD, Russo, A, Mueller, N, Pang, YP & Watowich, S 2009, 'Structure-based discovery of dengue virus protease inhibitors', Antiviral Research, vol. 82, no. 3, pp. 110-114. https://doi.org/10.1016/j.antiviral.2009.02.190
Tomlinson, Suzanne M. ; Malmstrom, Robert D. ; Russo, Andrew ; Mueller, Niklaus ; Pang, Yuan Ping ; Watowich, Stanley. / Structure-based discovery of dengue virus protease inhibitors. In: Antiviral Research. 2009 ; Vol. 82, No. 3. pp. 110-114.
@article{e219285690a7465b9cbffd8f2ce0c320,
title = "Structure-based discovery of dengue virus protease inhibitors",
abstract = "Dengue virus belongs to the family Flaviviridae and is a major emerging pathogen for which the development of vaccines and antiviral therapy has seen little success. The NS3 viral protease is a potential target for antiviral drugs since it is required for virus replication. The goal of this study was to identify novel dengue virus (type 2; DEN2V) protease inhibitors for eventual development as effective anti-flaviviral drugs. The EUDOC docking program was used to computationally screen a small-molecule library for compounds that dock into the P1 pocket and the catalytic site of the DEN2V NS3 protease domain apo-structure [Murthy, K., Clum, S., Padmanabhan, R., 1999. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J. Biol. Chem. 274, 5573-5580] and the Bowman-Birk inhibitor-bound structure [Murthy, K., Judge, K., DeLucas, L., Padmanabhan, R., 2000. Crystal structure of dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. J. Mol. Biol. 301, 759-767]. The top 20 computer-identified hits that demonstrated the most favorable scoring {"}energies{"} were selected for in vitro assessment of protease inhibition. Preliminary protease activity assays demonstrated that more than half of the tested compounds were soluble and exhibited in vitro inhibition of the DEN2V protease. Two of these compounds also inhibited viral replication in cell culture experiments, and thus are promising compounds for further development.",
keywords = "Dengue virus, Flavivirus, NS2B-NS3, Protease, Small-molecule inhibitor",
author = "Tomlinson, {Suzanne M.} and Malmstrom, {Robert D.} and Andrew Russo and Niklaus Mueller and Pang, {Yuan Ping} and Stanley Watowich",
year = "2009",
month = "6",
doi = "10.1016/j.antiviral.2009.02.190",
language = "English (US)",
volume = "82",
pages = "110--114",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Structure-based discovery of dengue virus protease inhibitors

AU - Tomlinson, Suzanne M.

AU - Malmstrom, Robert D.

AU - Russo, Andrew

AU - Mueller, Niklaus

AU - Pang, Yuan Ping

AU - Watowich, Stanley

PY - 2009/6

Y1 - 2009/6

N2 - Dengue virus belongs to the family Flaviviridae and is a major emerging pathogen for which the development of vaccines and antiviral therapy has seen little success. The NS3 viral protease is a potential target for antiviral drugs since it is required for virus replication. The goal of this study was to identify novel dengue virus (type 2; DEN2V) protease inhibitors for eventual development as effective anti-flaviviral drugs. The EUDOC docking program was used to computationally screen a small-molecule library for compounds that dock into the P1 pocket and the catalytic site of the DEN2V NS3 protease domain apo-structure [Murthy, K., Clum, S., Padmanabhan, R., 1999. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J. Biol. Chem. 274, 5573-5580] and the Bowman-Birk inhibitor-bound structure [Murthy, K., Judge, K., DeLucas, L., Padmanabhan, R., 2000. Crystal structure of dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. J. Mol. Biol. 301, 759-767]. The top 20 computer-identified hits that demonstrated the most favorable scoring "energies" were selected for in vitro assessment of protease inhibition. Preliminary protease activity assays demonstrated that more than half of the tested compounds were soluble and exhibited in vitro inhibition of the DEN2V protease. Two of these compounds also inhibited viral replication in cell culture experiments, and thus are promising compounds for further development.

AB - Dengue virus belongs to the family Flaviviridae and is a major emerging pathogen for which the development of vaccines and antiviral therapy has seen little success. The NS3 viral protease is a potential target for antiviral drugs since it is required for virus replication. The goal of this study was to identify novel dengue virus (type 2; DEN2V) protease inhibitors for eventual development as effective anti-flaviviral drugs. The EUDOC docking program was used to computationally screen a small-molecule library for compounds that dock into the P1 pocket and the catalytic site of the DEN2V NS3 protease domain apo-structure [Murthy, K., Clum, S., Padmanabhan, R., 1999. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J. Biol. Chem. 274, 5573-5580] and the Bowman-Birk inhibitor-bound structure [Murthy, K., Judge, K., DeLucas, L., Padmanabhan, R., 2000. Crystal structure of dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. J. Mol. Biol. 301, 759-767]. The top 20 computer-identified hits that demonstrated the most favorable scoring "energies" were selected for in vitro assessment of protease inhibition. Preliminary protease activity assays demonstrated that more than half of the tested compounds were soluble and exhibited in vitro inhibition of the DEN2V protease. Two of these compounds also inhibited viral replication in cell culture experiments, and thus are promising compounds for further development.

KW - Dengue virus

KW - Flavivirus

KW - NS2B-NS3

KW - Protease

KW - Small-molecule inhibitor

UR - http://www.scopus.com/inward/record.url?scp=64749108083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749108083&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2009.02.190

DO - 10.1016/j.antiviral.2009.02.190

M3 - Article

VL - 82

SP - 110

EP - 114

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 3

ER -